arrow
Return

The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource

delete2022-02-07
delete2
delete
OA
AI
V
Véronique Ouellet
A
Andrew Erickson
W
Wiley, Kathy
M
Morrissey, Colm
B
Berge, Viktor
C
Carlos S. Moreno
K
Kristin Austlid Taskén
D
Dominique Trudel
T
True, Lawrence D.
L
Lewis, Michael S.
S
Svindland, Aud
E
Ertunc, Onur
V
Vidal, Igor Damasceno
O
Osunkoya, Adeboye O.
J
Jones, Tracy
B
Bova, G. Steven
L
Lamminen, Tarja
A
Achtman, Ariel H.
B
Buzza, Mark
K
Kouspou, Michelle M.
B
Bigler, Steven A.
Z
Zhou, Xinchun
S
Stephen J. Freedland
M
Mes-Masson, Anne-Marie
G
Garraway, Isla P.
T
Trock, Bruce J.
T
Taimen, Pekka
S
Saad, Fred
T
Tuomas Mirtti
K
Knudsen, Beatrice S.
D
De Marzo, Angelo M. *
DOI:10.1158/1055-9965.EPI-21-0600delete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
Background: The need to better understand the molecular underpinnings of the heterogeneous outcomes of patients with prostate cancer is a pressing global problem and a key research priority for Movember. To address this, the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project constructed a set of unique and richly annotated tissue microarrays (TMA) from prostate cancer samples obtained from multiple institutions across several global locations. Methods: Three separate TMA sets were built that differ by purpose and disease state. Results: The intended use of TMA1 (Primary Matched LN) is to validate biomarkers that help determine which clinically localized prostate cancers with associated lymph node metastasis have a high risk of progression to lethal castration-resistant metastatic disease, and to compare molecular properties of high-risk index lesions within the prostate to regional lymph node metastases resected at the time of prostatectomy. TMA2 (Pre vs. Post ADT) was designed to address questions regarding risk of castration-resistant prostate cancer (CRPC) and response to suppression of the androgen receptor/androgen axis, and characterization of the castration-resistant phenotype. TMA3 (CRPC Met Heterogeneity)'s intended use is to assess the heterogeneity of molecular markers across different anatomic sites in lethal prostate cancer metastases. Conclusions: The GAP1-UTMA project has succeeded in combining a large set of tissue specimens from 501 patients with prostate cancer with rich clinical annotation. Impact: This resource is now available to the prostate cancer community as a tool for biomarker validation to address important unanswered clinical questions around disease progression and response to treatment.
Keywords:
PROTEIN EXPRESSION
PTEN LOSS
VALIDATION
SURVIVAL
CARCINOMA
BONE
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

C
Cancer Epidemiology Biomarkers and Prevention
IF:
3.4
Papers:
1.0W
Citations:
1.9W

Organization

S
Suleyman Demirel University
Scholars:
2.4K
Papers: 2.2K
Citations: 184
D
Durham VA Medical Center
Scholars:
751
Papers: 572
Citations: 2.1K
U
University of Turku
Scholars:
1.7W
Papers: 1.5W
Citations: 2.0W
U
universite de montreal
Scholars:
4.6W
Papers: 3.8W
Citations: 46
U
University of Washington
Scholars:
8.0W
Papers: 7.0W
Citations: 12.5W
U
university of oslo
Scholars:
4.2W
Papers: 3.5W
Citations: 53
T
Tampere University
Scholars:
1.4W
Papers: 1.3W
Citations: 1.4W
U
US Department of Veterans Affairs
Scholars:
3.8W
Papers: 3.3W
Citations: 47
J
Johns Hopkins University
Scholars:
10.2W
Papers: 8.8W
Citations: 13.0W
U
university of oxford
Scholars:
9.6W
Papers: 8.5W
Citations: 137
U
UCLA Jonsson Comprehensive Cancer Center
Scholars:
942
Papers: 673
Citations: 3.1K
E
Emory University
Scholars:
5.0W
Papers: 4.2W
Citations: 5.7W
C
Cedars Sinai Medical Center
Scholars:
1.3W
Papers: 1.1W
Citations: 23
U
University of Mississippi
Scholars:
9.5K
Papers: 7.9K
Citations: 5.8K
researcher View more organizations